Dexcom, Inc.

Metacure Limited

Cardiac Pacemakers, Inc.

Elira, Inc.

Paul Goode

James H Brauker

Apurv Ullas Kamath

Mark C Brister

Peter Koziar, Jr

Peter C Simpson

Shlomo Ben-Haim

Jack Pryor

Mark Allan Tapsak

James Patrick Thrower

Benny Rousso

Victoria E Carr-Brendel

Shai Policker

Irit Yaniv

Walid Haddad

Virender K Sharma

Jay M Miazga

Matthew Joseph Gani

Raul E Perez

Kaila Raby

Steven DiIanni

Harold Lebovitz

Luis Jose Malave

Peter I Hong

Brad Stengel

Edy Sofer

John L Faul

Anat Kliger

Bevil Hogg

A device for continuously monitoring glucose levels in a patient includes a lead assembly in electrical communication with an electronics assembly. The electronics assembly is configured to be positioned in the subcutaneous tissue and the lead assembly is configured to be positioned in a vessel of the patient, such as in a vein or in an epidural space. The lead assembly has a lumen, and includes at least one electrode in electrical communication with the electronics assembly.

Implantable glucose sensors and methods of glucose measurement configured for minimal sensor surface obstruction

Low power implantable glucose sensors and methods of glucose measurement

Methods and systems for measuring glucose having improved decay rates and lag times

The present specification discloses devices and methodologies for the treatment of GERD. Individuals with GERD may be treated by implanting a stimulation device within the patient's lower esophageal sphincter and applying electrical stimulation to the patient's lower esophageal sphincter, in accordance with certain predefined protocols. The presently disclosed devices have a simplified design because they do not require sensing systems capable of sensing when a person is engaged in a wet swallow, have improved energy storage requirements, enable improved LES function while concurrently delivering additional health benefits, and enable improved LES function post stimulation termination.

Device and implantation system for electrical stimulation of biological systems

There is provided in accordance with an exemplary embodiment of the invention a method of treating diabetic patients comprising measuring a triglyceride level in a diabetic patient and applying a diabetes treatment according to the triglyceride level. Optionally, there is provided a method of screening. Alternatively or additionally, there is provided a method of weight loss. Alternatively or additionally, there is provided a method of relatively reducing HOMA-IR levels. Alternatively or additionally, there is provided a method of relatively reducing blood pressure. An exemplary device to apply the treatment is described.

Method of treating a patient

The present invention relates generally to systems and methods for measuring an analyte in a host. More particularly, the present invention relates to systems and methods for transcutaneous measurement of glucose in a host.

Transcutaneous analyte sensor

A method is provided that includes providing a fundic impedance signal of a subject sensed during an initial calibration period using at least one implantable fundic sensor of an eating detection device. An indication is received of actual ingestion events of the subject during the initial calibration period. Using a cost function, an analysis is performed of the fundic impedance signal and the actual ingestion events. Responsively to the analysis, a threshold is set, the crossing of which by the fundic impedance signal is indicative of ingestion. The threshold is stored in a memory of the eating detection device. Other embodiments are also described.

Optimization of thresholds for eating detection

The present invention relates to an implantable cardioverter-defibrillator or pacemaker whose standard circuitry is used to trend a physiological cardiac parameter using intra-cardiac impedance measurements. The trend information may be used to predict the onset of a sudden cardiac death (SCD) event. By being able to predict the onset of an SCD event, patients and their physicians may be forewarned of a life-threatening event allowing them to respond accordingly. The trend information may also be used to predict the efficacy of cardiac-related medications, monitor progress of congestive heart failure, detect the occurrence of myocardial infarction, or simply track changes in sympathetic tone.

Method and apparatus for trending a physiological cardiac parameter

The present invention relates generally to systems and methods for increasing oxygen generation in electrochemical sensors in order to overcome the oxygen limitations. The preferred embodiments employ electrode systems with at least two electrodes in relatively close proximity to each other; wherein at least one electrode is configured to generate oxygen and at least one other electrode is configured to sense an analyte or a product of a reaction indicative of the concentration of analyte. The oxygen generated by the oxygen-generating electrode is available to the catalyst within a membrane system and/or the counter electrode, thereby enabling the electrochemical sensors of the preferred embodiments to function even during ischemic conditions.

Electrochemical sensors including electrode systems with increased oxygen generation

An analyte-measuring device, particularly an electrochemical sensor, is provided for measuring current values at multiple bias potential settings to assess the quality of the analyte measurement, identify interference in the signal, and calculate substantially interference-free analyte concentration measurements. The device and method are suitable for calculating substantially interference-free analyte concentration measurements when glucose is the analyte and acetaminophen is an interfering species.

Systems and methods for improving electrochemical analyte sensors

Growing community of inventors

Cherry Hill, NJ, United States of America

Paul Goode